The American Society for Radiation Oncology (ASTRO) strongly supports the nomination of Dr. Monica Bertagnolli as director of the National Institutes of Health (NIH). ASTRO commends her advocacy for research, innovation, and equity, particularly in cancer care. They look forward to collaborating with Dr. Bertagnolli to improve healthcare, including by enhancing clinical trial diversity and advancing cancer research. ASTRO believes she is the ideal leader for the NIH and urges the Senate to confirm her nomination promptly.
The American Society for Radiation Oncology (ASTRO) has expressed its unwavering support for the nomination of Dr. Monica Bertagnolli as the director of the National Institutes of Health (NIH). President Joseph R. Biden Jr.’s selection of Dr. Bertagnolli has garnered a strong endorsement from ASTRO, which recognizes her as an exceptional candidate with a profound commitment to advancing research, innovation, and equity within the medical field.
As the current leader of the National Cancer Institute (NCI), Dr. Bertagnolli has exhibited exceptional dedication and expertise in the realm of cancer research. Her exemplary track record positions her as a formidable advocate for driving progress in healthcare initiatives. ASTRO eagerly anticipates collaborating with Dr. Bertagnolli in her new capacity at the NIH, focusing on endeavors to enhance the American healthcare system. One such initiative is the pursuit of increased diversity in clinical trials, an essential aspect of promoting equitable healthcare. Additionally, ASTRO is eager to work closely with Dr. Bertagnolli to ensure that radiation oncologists play a significant role in realizing President Biden’s ambitious objective of reducing cancer mortality by 50% over the next 25 years.
Given that radiation therapy is a crucial treatment method for over half of all cancer patients, ASTRO recognizes the pivotal importance of Dr. Bertagnolli’s leadership in facilitating the achievement of this vital goal. ASTRO firmly believes that Dr. Bertagnolli possesses the ideal qualities and expertise required to guide the NIH during this critical juncture. The organization strongly urges the Senate to promptly confirm her nomination, acknowledging the urgent need for her effective leadership and visionary guidance.
